DOCSLIB.ORG

Substance Index for Volume 66

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Substance Index for Volume 66 The Journal of Antibiotics (2013) 66, 749–753 & 2013 Japan Antibiotics Research Association All rights reserved 0021-8820/13 www.nature.com/ja Substance Index for Volume 66 (3R,4R)-4-Acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy) 161 A26771B 123 ethyl]-2-azetidinone AB3217-A 123 4-O-(400-O-Acetyl-a-L-rhamnopyranosyl)-ellagic acid 123 Acidomycin 371 Bedaquiline 571 Aclacinomycin A, N-benzyl- 165 4-O-Benzoyl-2,3,6-trideoxy-3-C-methyl-3- 131 Actinopyrone A 123 trifluoroacetamido-a,b-L-lyxo-hexopyranosyl acetate Actinorhodin 387 4-O-Benzyl-2,3,6-trideoxy-3-C-methyl-3-azido-a,b-L-lyxo- 131 Actinorhodin, diepoxy 295 hexopyranosyl acetate AFN-1252 571 4-O-Benzyl-2,3,6-trideoxy-3-C-methyl-3- 131 Albaflavenone 387 trifluoroacetamido-a,b-L-lyxo-hexopyranosyl acetate Albocycline 303 (S, Z)-3-Benzylidene-6-isopropylpiperazine-2,5-dione 31 Allosamizoline 123 (S, Z)-3-Benzylidene-6-methylpiperazine-2,5-dione 31 N-Allyl-aclacinomycin A 165 3-Benzylpiperazine-6-(4-methoxybenzylidene)-2,5-dione 31 (4R*,6R*,8S*)-8-Allyl-9,9-dimethyl-1-methoxy-4- 141 Bhimamycin F, H, I 719 prenyl-6-((triisopropylsilyloxy)methyl)bicyclo Biapenem 571 [3.3.1]non-1-ene-3,5-dione Biemodin 491 (4S*,6R*,8S*)-3-(8-Allyl-9,9-dimethyl-1-methoxy-6- 141 Brartemicin analogs 531 ((triisopropylsilyloxy)methyl)bicyclo[3.3.1]non-1- Brilacidin 571 ene-3,5-dione-4-yl)methyl)-2,2-dimethyloxirane (3S)-4-Bromo-2,3-dimethylbut-1-ene 147 (4S*,6R*,8S*,18S*)-8-Allyl-18-(1-hydroxy-1-methylethyl) 141 (2E,5R)-1-tert-Butyldiphenylsilyloxy-5- 155 -9,9-dimethyl-6-((triisopropylsilyloxy)methyl)-31- methanesulfonyloxy-2-methylhex-2-ene oxatricyclo[6.3.1.03,4]dodec-2-ene-1,5-dione BAL30072 571 (4S*,6R*,8S*,18S*)-8-Allyl-18-(1-methyl-1- 141 BC-3781 571 trimethylsilyloxyethyl)-9,9-dimethyl-6- BE-14106 431 ((triisopropylsilyloxy)methyl)-31-oxatricyclo BE-52440A 107, 123 [6.3.1.03,4]dodec-2-ene-1,5-dione BE-54238B 107 AM6898D 123 BE-5423B 123 Amiclenomycin 371 Amikacin 61 Cabanillasin 617 (11R)-4-Aminoalcohol quinoline derivatives 683 Cadazolid 371, 571 (11S)-4-Aminoalcohol quinoline derivatives 683 Calbistrin A 123 5¢-Amino-5¢-N-(biotinyl)sulfamoyl-5¢-deoxyadenosine 371 Caloporoside, deacetyl- 123 (2E,4E,6E)-2-Amino-5-methylhepta-4,6-diene 155 Caprazene, 500-N-t-butoxycarbonyl 171 Amphidinolide N 277 Caprazene 4-butylanilide 171 Ampicillin 511 Caprazene tetradecylamide 171 Anidulafungin 701 Caprazene tridecyl ester 171 Apramycin 107, 123 Carbapen-2-em-3-carboxylic acid 401 Aprosamine 107 Carbapenems, olivanic acid-type 401 D-Arbinose 107 Carbomycin B 123 Arbekasin 273 Cefazolin 511 epi-Arphamenine A 123 Cefmetazole 97 Asterriquinone B1 123 Cefotiam 511 Asterriquinone B1, demethyl 123 Cefoxitin 97 Aureoverticillalactam 431 Cefozopran 107 Auriclosene 571 Ceftaroline 571 Avarofloxacin 571 Ceftazidime 571, 593 Avibactam 571 Ceftolozane 571 Azepinomycin 123 Cephabacins 401 (2E,4E,6E)-2-Azido-5-methylhepta-4,6-diene 155 Cephalosporins 401 (2E,5S)-5-Azido-1-tert-butyldiphenylsilyloxy-2- 155 Cephamycin 401 methylhex-2-ene Chloramlincomycin 371 (2E,5S)-5-Azido-2-methylhex-2-en-1-al 155 Chloramphenicol 97 (2E,5S)-5-Azido-2-methylhex-2-en-1-ol 155 [5-(4-Chlorophenyl)-5-hydroxy-3-(trifluoromethyl)- 371 Aztreonam 571 4,5-dihydro-1H-pyrazol-1-yl](m-tolyl)methanone Substance Index 750 Chymostatin A, B, C 123 (3R,6R)-3-[(1,3-Dioxolan-2-yl)methyl]-3,6,7- 147 Cilastatin 571 trimethylocta-1,7-dien-4-one Ciprofloxacin 593 (5R,6R,9R)-6-((1,3-Dioxolan-2-yl)methyl)-6,8,9- 147 Citreorosein 219 trimethyl-1-oxaspiro[4.5]deca-3,7-dien-2-one 5S Clavams 401 (5S,6R,9R)-6-((1,3-Dioxolan-2-yl)methyl)-4- 147 Clavulanic acid 401, 411 methoxy-6,8,9-trimethyl-1-oxaspiro[4.5]deca-3,7- Clindamycin 97, 511 dien-2-one Cochleamycin A 107, 123 DS-8587 571 epi-Cochlioquinone A 123 Coelichelin 387 Ebelactone A 421 Coelimycin P1 387 Elaiomycins K, L 85 Colistin 705 Elaiophylin 123 Coriolin 123 Emodin 219 Cuevaene A 563 Epothilone O 285 Curvalarol A, B 735 Eravacycline 571 Curvularone A 287 Erbstatin 123 Cyclomenol A 431 (11R,12S)-Erythro-mefloquine, (À)-, (+)- 683 Cyclophellitol 123 Erythromycin A 107, 123 Cylindrol A5 23 2-(Ethoxycarbonyl)propanoic acid 147 Cystacyclin 743 Exeporfinium chloride 571 CB-182,804 371 ES-242-4, -5 123 CBR-2092 371 CG400549 571 Falcitidin 259 Fidaxomicin 571 Dalbavancin 571 Finafloxacin 571 Danofloxacin 629 Fluconazole 651 Delafloxacin 571 Fosfomycin 625, 709 Delamanid 571 Desferrioxamine 387 Garsubellin A 141 (4S*,6R*,8S*,18S*)-2,8-Diallyl-18-(1-hydroxy-1- 141 Geldanamycin, 19-S-methyl 499 methylethyl)-6-(1-hydroxy-2-methylpropyl)-9,9- Gentamicin 511 dimethyl-31-oxatricyclo[6.3.1.03,4]dodec-2-ene- Geosmin 387 1,5-dione Germicidin 387 (4S*,6R*,8S*,18S*)-2,8-Diallyl-18-(1-hydroxy-1- 141 Gualamycin 123 methylethyl)-6-hydroxymethyl-9,9-dimethyl-31- GSK1322322 571 oxatricyclo[6.3.1.03,4]dodec-2-ene-1,5-dione (4S*,6R*,8S*,18S*)-2,8-Diallyl-18-(1-hydroxy-1- 141 Herbimycin A 123 methylethyl)-6-isobutyryl-9,9-dimethyl-31-oxatricy- Herbimycin A, 17,19-dimethyltio 499 clo[6.3.1.03,4]dodec-2-ene-1,5-dione Hibarimicinone 107, 123 (4S*,6R*,8S*,18S*)-2,8-Diallyl-18-(1-hydroxy-1- 141 Hirsutene 123 methylethyl)-9,9-dimethyl-31-oxatricyclo[6.3.1.03,4] Hitachimycin 431 dodec-2-ene-1,5-dione-6-carbaldehyde Hopene 387 (4S*,6R*,8S*,18S*)-2,8-Diallyl-18-(1-methyl-1- 141 1-Hydroxy-4-methoxy-2-naphthoic acid 31 trimethylsilyloxyethyl)-9,9-dimethyl-6- ((triisopropylsilyloxy)methyl)-31-oxatricyclo IMC0301B 243 [6.3.1.03,4]dodec-2-ene-1,5-dione Imipenem 97, 511, 571 (3S)-2,3-Dimethyl-4-(p-toluenesulfonyl)oxybut-1-ene 147 Incednam 155 Dinapinone AB1, AB2, AC1, AC2, AD1, AD2, 179 Incednine 431, 691 AE1, AE2 Indanostatin 731 Diorcinol B, C, D, E 539 Indisocin 123 (1S,2R,5R)-2-((1,3-Dioxolan-2-yl)methyl)-1-((Z)-1- 147 Intervenolin 543 methoxy-2-(ethoxycarbonyl)ethenyl)-2,4,5- Isorenieratene 387 trimethylcyclohex-3-en-1-ol Isoretronecanol 123 (1S,2R,5R)-2-((1,3-Dioxolan-2-yl)methyl)-1 147 Isorhodoptilometrin 219 ([2-(ethoxycarbonyl)ethynyl)-2,4,5-trimethylcyclohex- 3-en-1-ol JBIR-130, -131, 132 235 (2R)-2-((1,3-Dioxolan-2-yl)methyl)-2-methylbut- 147 3-en-1-ol Kalafungin 107, 123 (2R)-2-((1,3-Dioxolan-2-yl)methyl)-2-methylbut-3-enal 147 Kanamycin A 107, 123 (2R,5R)-2-((1,3-Dioxolan-2-yl)methyl)-2,4,5- 147 Kanamycin B, C 123 trimethylcycohex-3-en-1-one KB425796-A, -C 465, 473 The Journal of Antibiotics Substance Index 751 KB425796-B, -D, -E, -F, -G, -H, -I, -J, -K 473 Methyl 2-hydroxy-3-(4-O-benzoyl-2,3,6-trideoxy-3-C- 131 K1115 B1a,B1b 123 methyl-3-trifluoroacetamido-b-L-lyxo- KD16-U1 123 hexopyranosyl)-6-(prop-2-ene-1-yloxy)benzoate KPI-10 (WQ-3813) 571 Methyl 2-hydroxy-3-(4-O-benzyl-2,3,6-trideoxy-3-C- 131 methyl-3-azido-b-L-lyxo-hexopyranosyl)-6- Lactonamycin 107, 123 (prop-2-ene-1-yloxy)benzoate Lagunamycin 123 Methyl 2-hydroxy-3-(4-O-benzyl-2,3,6-trideoxy-3-C- 131 Langkocycline A1, A2, A3, B1, B2 609 methyl-3-trifluoroacetamido-b-L-lyxo-hexopyranosyl)- Leucomycin A3 107, 123 6-(prop-2-ene-1-yloxy)benzoate Levofloxacin 511, 709 N-Methylindisocin 123 Lincomycin derivatives 195 O-Methyl methyl 4,6-O-benzylidene-2,3-dideoxy-a- 131 Lincophenicol 371 D-erythro-hexopyranosid-3-ulose oxime Linearolide A, B 333 Methyl 3-O-(tert-butyldimethylsilyl)-6-deoxy-a-D- 147 Linezolid 273 glucopyranoside Linfuranone A 675 Methyl 4,6-O-benzylidene-2,3-dideoxy-3- 131 Linieodolide A, B 89 (N-methoxytrifluoroacetamido)-3-C-methyl-a-D-ribo- Lorneic acid C, D 347 hexo-pyranoside Luminacin C1, C2 123 Methyl 4,6-O-benzylidene-2,3-dideoxy-3-C-methyl-3- 131 Lymphostin 123 (methoxyamino)-a-D-ribo-hexopyranoside LCB01-0371 571 Methyl 4,6-O-benzylidene-2,3-dideoxy-3-C-methyl-3- 131 LFF-571 571 trifluoroacetamido-a-D-ribo-hexopyranoside LL-37 571 Methyl 4-O-benzoyl-2,3,6-trideoxy-3-C-methyl-3- 131 LL-Z1640-2 123 trifluoroacetamido-a-D-erythro-hex-5-enopyranoside LTX-109 571 Methyl 4-O-benzoyl-2,3,6-trideoxy-3-C-methyl-3- 131 trifluoroacetamido-a-D-ribo-hexopyranoside (epi-8) Macplocimine A 443 Methyl 4-O-benzoyl-2,3,6-trideoxy-3-C-methyl-3- 131 Macrocyclic engelhardione analogs 319 trifluoroacetamido-b-L-lyxo-hexopyranoside Macrolactin X, Y, Z 89 Methyl 4-O-benzoyl-6-bromo-2,3,6-trideoxy-3-C- 131 Maniwamycin A, B 123 methyl-3-trifluoroacetamido-a-D-ribo-hexopyranoside MB12, 13 371 Methyl 4-O-benzyl-2,3,6-trideoxy-3-C-methyl-3-amino- 131 MBJ-0009, -0010 567 b-L-lyxo-hexopyranoside MBJ-0011, -0012, -0013 299 Methyl 4-O-benzyl-2,3,6-trideoxy-3-C-methyl-3-azido- 131 MBJ-0020 563 b-L-lyxo-hexopyranoside MBJ-0038, -0039, -0040 727 Methyl 4-O-benzyl-2,3,6-trideoxy-3-C-methyl-3- 131 MBX 1066, 1090, 1113, 1128, 1162 47 dimethylamino-b-L-lyxo-hexopyranoside Medermycin 107, 123 Methyl 4-O-benzyl-2,3,6-trideoxy-3-C-methyl-3- 131 Methicillin 517 trifluoroacetamido-b-L-lyxo-hexopyranoside (3Z,6Z)-3-(4-Methoxybenzylidene)-6- 31 Methylenomycin 387 (2-methylpropylidene)piperazine-2,5-dione Methylfurans 387 per-6-(4-Methoxylbenzyl)-amino-6-deoxy-b- 517 (2Z,4E,6E,8E,10R,11S,12Z)-1-((2E,4E,6E)-5-Methylhepta- 155 cyclodextrin 4,6-diene)amide-10,11-bis(triethylsilyloxy)-13-iodo-2- 2-Methoxynaphthalene-1,4-dione 31 methoxy-4,10,16-trimethyltrideca-2,4,6,8,12-pentaene Methyl 2,3,6-trideoxy-3-C-methyl-3-trifluoroacetamido- 131 (2Z,4E,6E,8E,10R,11S,12Z,14E,16E,18E)-1-((2E,4E,6E)- 155 b-L-lyxo-hexopyranoside 5-Methylhepta-4,6-diene)amide-10,11- Methyl 2,3-di-O-(tert-butyldimethylsilyl)-6-deoxy-4-O- 147 bis(triethylsilyloxy)-13-iodo-2-methoxy-4,10,16- ((2R)-2-((1,3-dioxolan-2-yl)methyl)-2-methyl-3- trimethylnonadeca-2,4,6,8,12,14,16-heptaene butenoyl)-a-D-glucopyranoside (1E,3E,5E)-3-Methylhex-1,3,5-trien-1-tributylstannane 155 Methyl 2,3-di-O-(tert-butyldimethylsilyl)-6-deoxy-4-O- 147 Metronidazole 97 ((2R)-2-ethoxycarbonyl-2-formylmethylpropanoyl)-
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7,879,798 B1 Aufseeser (45) Date of Patent: Feb
    US007879798B1 (12) United States Patent (10) Patent No.: US 7,879,798 B1 Aufseeser (45) Date of Patent: Feb. 1, 2011 (54) COMPOSITION FOR INDOLENT WOUND Mazzotta, M.Y. “Nutrition and Wound Healing.” J. Am. Podiatr. Med. HEALING AND METHODS OF USE Assoc. 84(9): 456-462, Sep. 1994. THEREFOR Niedermeier, S. "Tierexperimentelle Untersuchungen Zur Frage der Behandlung von Hornhautlasionen Animal experiment studies on the problem of treating corneal lesions.” Klin. Monatsbl. (75) Inventor: Leslie S. Aufseeser, Lakewood, NJ (US) Augenheilkd (Germany, West), 190 (1):28-9, Jan. 1987. Seifter, E. etal. “Impaired Wound Healing in Streptozotocin diabetes. (73) Assignee: Regenicel, Inc., Lakewood, NJ (US) Prevention by supplemental Vitamin A.” Ann. Surgery (US). 194(1): 42-50, Jul. 1981. (*) Notice: Subject to any disclaimer, the term of this Gilmore, O.J.A. etal. “Aetiology and prevention of wound infection patent is extended or adjusted under 35 in appendicetomy.” British Journal of Surgery, 61:281-287. Mar. U.S.C. 154(b) by 594 days. 1974. Lowenfels, Albert B. “Viewpoints: Wound Healing With No Oint (21) Appl. No.: 11/895,474 ment, Non-antibiotic Ointment, or Antibiotic Ointment”. Medscape General Surgery. 8(2), 2006. (22) Filed: Aug. 24, 2007 United States Food and Drug Administration. “First Aid Antibiotic Drug Products”. Code of Federal Regulations, Title 21, vol. 5, Chap (51) Int. Cl. ter I, Part 333, Subpart B, pp. 222-225, Apr. 1, 2006. A6 IK 38/12 (2006.01) Akpek, EK et al. "A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis.” (52) U.S.
    [Show full text]
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • Oxazolidinones for TB
    Oxazolidinones for TB: Current Status and Future Prospects 12th International Workshop on Clinical Pharmacology of Tuberculosis Drugs London, UK 10 September 2019 Lawrence Geiter, PhD Disclosures • Currently contract consultant with LegoChem Biosciences, Inc., Daejeon, Korea (LCB01-0371/delpazolid) • Previously employed with Otsuka Pharmaceutical Development and Commercialization, Inc. (delamanid, OPC-167832, LAM assay) What are Oxazolidinones • A family of antimicrobials mostly targeting an early step in protein synthesis • Cycloserine technically oxazolidinone but 2-oxazolidinone different MOA and chemical properties • New generation oxazolidinones bind to both 50S subunit and 30S subunit • Linezolid (Zyvox) and Tedizolid (Sivestro) approved for drug resistant skin infections and community acquired pneumonia Cycloserine • Activity against TB demonstrated in non- clinical and clinical studies • Mitochondrial toxicity >21 days limits use in TB treatment Linezolid Developing Oxazolidinones for TB Compound Generic Brand Sponsor Development Status TB Code- Activity/Trials PNU-100766 Linezolid Zyvox Pfizer Multiple regimen Yes/Yes TR-201 Tedizolid Sivextro Merck Pre-clinical efficacy Yes/No PNU-100480 Sutezolid Pfizer Multiple regimen studies Sequella Yes/Yes (PanACEA) TB Alliance LCB01-0371 Delpazolid LegoChem Bio EBA trial recruitment completed Yes/Yes TBI-223 - Global Alliance SAD trial launched Yes/Yes AZD5847 Posizolid AstraZenica Completed EBA Yes/No RX-1741 Radezolid Melinta IND for vaginal infections ?/No RBX-7644 Ranbezolid Rabbaxy None found ?/No MRX-4/MRX-1 Contezolid MicuRx Skin infections Yes/No U-100592 Eperezolid ? No clinical trials ?/No PK of Oxazolidinones in Development for TB Steady State PK Parameters Parameter Linezolid 600 Delpazolid 800 mg QD2 mg QD3 Cmax (mg/L) 17.8 8.9 Cmin (mg/L) 2.43 0.1 Tmax (h) 0.87 0.5 T1/2 (h) 3.54 1.7 AUC0-24 (µg*h/mL) 84.5 20.1 1 MIC90 (µg/mL) 0.25 0.5 References 1.
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • FDA Approved Antibacterial Drugs in 2018 and 2019
    DISCOVERIES 2019, Oct-Dec, 7(4): e102 DOI: 10.15190/d.2019.15 FDA Approved Antibacterial Drugs in 2018 and 2019 Focused REVIEW FDA approved antibacterial drugs: 2018-2019 Stefan Andrei1,2,3,*, Gabriela Droc,1,2,Gabriel Stefan,2,4 1Department of Anesthesia and Intensive Care, Fundeni Clinical Institute, Bucharest, Romania 2Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 3Université Paris Sud XI, Faculté de Médecine, Le Kremlin-Bicêtre, France 4Dr. Davila Teaching Hospital of Nephrology, Bucharest, Romania * Corresponding authors: Stefan Andrei, MD, Department of Anesthesia and Intensive Care, Fundeni Clinical Institute, 258 Soseaua Fundeni, Bucharest, 022328, Romania; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Université Paris Sud XI, Faculté de Médecine, 63 Rue Gabriel Péri, 94270 Le Kremlin-Bicêtre, France; [email protected] Submission: Dec. 29, 2019; Revised: Dec. 31, 2019; Accepted: Dec. 31, 2019; Published: Dec. 31, 2019; Citation: Andrei S, Droc G, Stefan G. FDA approved antibacterial drugs: 2018-2019. Discoveries 2019, October-December; 7(4); e102. DOI:10.15190/d.2019.15 ABSTRACT noninvasive Escherichia Coli-caused travelers' Bacterial resistance to existent antibiotherapy is a diarrhea. Two combinatorial strategies were perpetual internationally-recognized problem. Year approved for complicated urinary tract infections, after year, there is a continuous need for novel complicated intra-abdominal infections (imipenem, antibacterial drugs and this research and cilastatin and relebactam) and lung tuberculosis development efforts recently resulted in few new (pretomanid in combination with bedaquiline and drugs or combination of drugs proposed for the use linezolid). Lefamulin is a semisynthetic into the clinic. pleuromutilin antibiotic for community-acquired This review focuses on the novel US FDA bacterial pneumonia, while cefiderocol, a approved antibacterial agents in the last two years cephalosporin antibiotic is the last antibacterial drug (2018-2019).
    [Show full text]
  • WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 38/43 (2006.01) A61K 47/36 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 38/50 (2006.01) A61K 9/S0 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61K 33/44 {2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US20 17/039672 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 28 June 2017 (28.06.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Langi English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/355,599 28 June 2016 (28.06.2016) US KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]
  • SEYSARA™ (Sarecycline) Tablets for Oral Use
    • If Clostridium difficile Associated Diarrhea (antibiotic associated colitis) HIGHLIGHTS OF PRESCRIBING INFORMATION occurs, discontinue SEYSARA. (5.2) These highlights do not include all the information needed to use • Central nervous system side effects, including light-headedness, SEYSARA™ safely and effectively. See full prescribing information for dizziness or vertigo, have been reported with tetracycline use. Patients SEYSARA™. who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery. These symptoms may disappear SEYSARA™ (sarecycline) tablets for oral use. during therapy and may disappear when the drug is discontinued. (5.3) Initial U.S. Approval: 2018 • SEYSARA may cause intracranial hypertension. Discontinue SEYSARA if symptoms occur. (5.4) • Photosensitivity can occur with SEYSARA. Patients should minimize or -----------------------------INDICATIONS AND USAGE-------------------------- avoid exposure to natural or artificial sunlight. (5.5) SEYSARA™ is a tetracycline-class drug indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in -------------------------------ADVERSE REACTIONS------------------------------ patients 9 years of age and older. (1) Most common adverse reaction (incidence ≥ 1%) is nausea. (6.1) Limitations of Use To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1- Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have 800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. not been established. SEYSARA has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to ------------------------------DRUG INTERACTIONS------------------------------- maintain the effectiveness of other antibacterial drugs, SEYSARA should be • Oral retinoids: avoid coadministration. (5.4, 7.1) used only as indicated [see Warnings and Precautions (5.6)].
    [Show full text]
  • Omadacycline
    Late Stage, Novel Antibiotics September, 2015 10/28/2015 1 Third-party information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, and should not be construed as a representation by, Paratek Pharmaceuticals, Inc. (“Paratek”). The information contained in this presentation is accurate only as of the date hereof. “Paratek” and the Paratek logo are trademarks and service marks of Paratek. All other trademarks, service marks, trade names, logos and brand names identified in this presentation are the property of their respective owners. Forward-Looking Statements / Risk Factors This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about our strategy, future operations, future financial position, future revenue, clinical development plans and timing, projected costs, prospects, plans, objectives of management, potential use and effectiveness of our product candidates, expected market growth, the market opportunity for and the market acceptance of our product candidates, and the strength of, and protection offered by, our intellectual property position. Examples of such statements include, but are not limited to, statements relating to the potential clinical risks and efficacy of, and market opportunities for, our product candidates, including Omadacycline and Sarecycline, the timing of clinical development of, and regulatory approval for, our product candidates, and the nature and timing of our collaboration agreements with respect to our product candidates. The words “anticipate,” “estimate,” “expect,” “potential,” “believe,” “will” and similar terms and phrases are used to identify forward-looking statements.
    [Show full text]
  • Download (12Mb)
    A Thesis Submitted for the Degree of PhD at the University of Warwick Permanent WRAP URL: http://wrap.warwick.ac.uk/110352 Copyright and reuse: This thesis is made available online and is protected by original copyright. Please scroll down to view the document itself. Please refer to the repository record for this item for information to help you to cite it. Our policy information is available from the repository home page. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications THE BRITISH LIBRARY BRITISH THESIS SERVICE THE DISTRIBUTION OF PHENOTYPIC AND GENOTYPIC CHARACTERS WITHIN STREPTOMYCETES AND THEIR RELATIONSHIP TITLE . TO ANTIBIOTIC PRODUCTION. AUTHOR........ Lesley Phillips, DEGREE.................................................... AWARDING BODY _ TI. .. The University of Warwick, THESIS NUMBER THIS THESIS HAS BEEN MICROFILMED EXACTLY AS RECEIVED The quality of this reproduction is dependent upon the quality of the original thesis submitted for microfilming. Every effort has been made to ensure the highest quality of reproduction. Some pages may have indistinct print, especially if the original papers were poorly produced or if the awarding body sent an inferior copy. If pages are missing, please contact the awarding body which granted the degree. Previously copyrighted materials (journal articles, published texts, etc.) are not filmed. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that Its copyright rests with its author and that no information derived from it may be published without the author's prior written consent. Reproduction of this thesis, other than as permitted under the United Kingdom Copyright Designs and Patents Act 1988, or under specific agreement with the copyright holder, is prohibited.
    [Show full text]
  • From Sugar Based Bio Renewable Resources to New Chemical Building Blocks and Bioactive Molecules
    Raquel Alexandra Germano Nunes Licenciatura em Química Aplicada From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Co-orientador: Rafael Filipe Teixeira Arbuéz Gomes, MSc, FF-UL Presidente: Prof. Doutora Paula Cristina de Sério Branco, FCT-UNL Arguente: Prof. Doutora Luísa Maria da Silva Pinto Ferreira, FCT-UNL Vogal: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Março 2017 LOMBADA Raquel Nunes Raquel From sugar based bio renewable resources to new chemical building blocks and bioactive molecules bioactive and blocks chemical new building to resources renewable bio based sugar From 2017 Raquel Alexandra Germano Nunes Licenciatura em Química Aplicada From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Co-orientador: Rafael Filipe Teixeira Arbuéz Gomes, MSc, FF-UL Presidente: Prof. Doutora Paula Cristina de Sério Branco, FCT-UNL Arguente: Prof. Doutora Luísa Maria da Silva Pinto Ferreira, FCT-UNL Vogal: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Março 2017 From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Copyright © Raquel Alexandra Germano Nunes, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa. A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por outro qualquer meio conhecido ou que venha a ser inventado e de divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor.
    [Show full text]
  • Antibiotic Discovery
    ANTIBIOTIC DISCOVERY RESISTANCE PROFILING OF MICROBIAL GENOMES TO REVEAL NOVEL ANTIBIOTIC NATURAL PRODUCTS By CHELSEA WALKER, H. BSc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the Degree Master of Science McMaster University © Copyright by Chelsea Walker, May 2017 McMaster University MASTER OF SCIENCE (2017) Hamilton, Ontario (Biochemistry and Biomedical Sciences) TITLE: Resistance Profiling of Microbial Genomes to Reveal Novel Antibiotic Natural Products. AUTHOR: Chelsea Walker, H. BSc. (McMaster University) SUPERVISOR: Dr. Nathan A. Magarvey. COMMITTEE MEMBERS: Dr. Eric Brown and Dr. Michael G. Surette. NUMBER OF PAGES: xvii, 168 ii Lay Abstract It would be hard to imagine a world where we could no longer use the antibiotics we are routinely being prescribed for common bacterial infections. Currently, we are in an era where this thought could become a reality. Although we have been able to discover antibiotics in the past from soil dwelling microbes, this approach to discovery is being constantly challenged. At the same time, the bacteria are getting smarter in their ways to evade antibiotics, in the form of resistance, or self-protection mechanisms. As such is it essential to devise methods which can predict the potential for resistance to the antibiotics we use early in the discovery and isolation process. By using what we have learned in the past about how bacteria protect themselves for antibiotics, we can to stay one step ahead of them as we continue to search for new sources of antibiotics from bacteria. iii Abstract Microbial natural products have been an invaluable resource for providing clinically relevant therapeutics for almost a century, including most of the commonly used antibiotics that are still in medical use today.
    [Show full text]